JPRN-UMIN000017675已完成2 期
A study of neoadjuvant nab-paclitaxel followed by FEC for luminal B-like (HER2-negative) and triple-negative breast cancer - A study of neoadjuvant nab-paclitaxel followed by FEC for HER2-negative breast cancer
Kyushu Breast Cancer Study Group (KBC-SG)0 个研究点目标入组 94 人开始时间: 2015年5月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) clinically important cardiac disorder and past history of this 2) Severe medical disorders (uncontrolled DM, hypertension, renal failure, liver failure, clinically significant infection and mental disorders) 3) pregnant and nursing female 4) active double cancer 5) lung fibrosis and intestinal pneumonisa 6) allergy reaction for drugs is using in this study 7) Others
研究者
相似试验
已完成
2 期
Phase II study of neoadjuvant nab-paclitaxel and trastuzumab for ER negative and HER2 positive breast cancerER negative and HER2 positive breast cancerJPRN-UMIN000019616Osaka Medical College18
已完成
不适用
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
已完成
2 期
A multicenter study of adjuvant nab-paclitaxel followed by FEC for early breast cancerPrimary breast cancerJPRN-UMIN000029836Kyushu Breast Cancer Study Group (KBC-SG)60
尚未招募
2 期
Phase II neoadjuvant trial of nab-Paclitaxel+Pertuzumab+Trastuzumab followed by Anthracycline based regimen in patients with operable Her2 positive breast cancerbreast cancerJPRN-UMIN000038715Osaka Medical College35
招募中
不适用
Feasibility study of adjuvant nab-paclitaxel in breast cancerbreast cancerJPRN-UMIN000007725Graduate school of medicine,Chiba University55